Edgewise Therapeutics

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive…